New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease. The drug ...

Alzheimer’s Research UK said the announcement “also risks signalling that the UK is no longer a good place to launch new dementia treatments”. Donanemab, manufactured by pha ...

The Alzheimer’s Association has set its annual Walk to End Alzheimer’s for Saturday, Oct. 26, at Trinity United Methodist ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

On the frontier of some of biopharma's lucrative markets, one competitor's stumble can be a win for one of its rivals. And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road ...

In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...

Having these warning signs checked out could provide an opportunity to delay or even prevent the onset of dementia or Alzheimer's.

Right now across the country, tens of millions of older adults and people with serious disabilities have a choice to make: whether to stick with their current Medicare option, or change during Open ...